Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (270)	8/29/2004 10:19:34 PM
From: scaram(o)uche	Respond to of 946

Erik: >> Friday, August 20, 2004 << just in case you hadn't noticed. Cheers! Rick

To: Icebrg who wrote (270)	8/31/2004 11:55:43 AM
From: Icebrg	Respond to of 946

Cell Therapeutics, Inc. Announces Exercise of Underwriters' Common Stock Over-Allotment Option Tuesday August 31, 10:31 am ET SEATTLE, Aug. 31 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced the underwriters of its recent 9,000,000 share common stock public offering exercised their over-allotment option and purchased 1,350,000 additional shares of common stock from CTI at a price of $4.75 per share minus the underwriting discounts. CTI sold a total of 10,350,000 shares of common stock in the offering, including the shares covered by the exercised over-allotment option, for aggregate gross proceeds of approximately $49.16 million. UBS Securities LLC and CIBC World Markets acted as joint book-running managers in the offering. WR Hambrecht + Co, LLC, Delafield Hambrecht, Inc. and Punk, Ziegel & Company, L.P. acted as co-managers.